Your browser doesn't support javascript.
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
Roozendaal, Ramon; Solforosi, Laura; Stieh, Daniel J; Serroyen, Jan; Straetemans, Roel; Dari, Anna; Boulton, Muriel; Wegmann, Frank; Rosendahl Huber, Sietske K; van der Lubbe, Joan E M; Hendriks, Jenny; Le Gars, Mathieu; Dekking, Liesbeth; Czapska-Casey, Dominika N; Guimera, Nuria; Janssen, Sarah; Tete, Sarah; Chandrashekar, Abishek; Mercado, Noe B; Yu, Jingyou; Koudstaal, Wouter; Perez-Ruixo, Juan J; Sadoff, Jerry; Barouch, Dan H; Schuitemaker, Hanneke; Zahn, Roland.
  • Roozendaal R; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Solforosi L; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Stieh DJ; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Serroyen J; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Straetemans R; Janssen R&D, Beerse, Belgium.
  • Dari A; Janssen R&D, Beerse, Belgium.
  • Boulton M; Janssen R&D, Beerse, Belgium.
  • Wegmann F; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Rosendahl Huber SK; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • van der Lubbe JEM; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Hendriks J; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Le Gars M; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Dekking L; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Czapska-Casey DN; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Guimera N; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Janssen S; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Tete S; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Chandrashekar A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Koudstaal W; Lucidity Biomedical Consulting, Granada, Spain.
  • Perez-Ruixo JJ; Janssen R&D, Beerse, Belgium.
  • Sadoff J; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Schuitemaker H; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Zahn R; Harvard Medical School, Boston, MA, USA.
Nat Commun ; 12(1): 5877, 2021 10 07.
Article in English | MEDLINE | ID: covidwho-1462003
ABSTRACT
Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We show that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of Spike-binding and neutralizing antibodies, indicating that Ad26.COV2.S could confer durable protection in humans and immunological correlates of protection may enable the prediction of durability of protection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26117-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26117-x